Colorectal Cancer Stocks List

Related ETFs - A few ETFs which own one or more of the above listed Colorectal Cancer stocks.

Colorectal Cancer Stocks Recent News

Date Stock Title
May 17 REGN More than $9 Million Awarded to High School Scientists and Engineers at the Regeneron International Science and Engineering Fair 2024
May 17 ERAS Erasca stock climbs 10% amid pipeline restructuring, equity offering
May 17 REGN Regeneron wins temporary restraining order preventing Eylea generic launch
May 17 ERAS Erasca restructures; Novartis moves to complete MorphoSys deal
May 17 ERAS DXC Technology Issues Weak Outlook, Joins Take-Two Interactive And Other Big Stocks Moving Lower In Friday's Pre-Market Session
May 17 ERAS Erasca prices $160M equity offering
May 17 ERAS Erasca Announces Strategic In-Licensing of RAS-Targeting Franchise
May 17 ERAS Erasca Announces Pricing of Underwritten Offering of Common Stock
May 16 MYGN New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer
May 16 MYNZ Pfizer, AstraZeneca, Sanofi And Mainz Biomed To Uplevel Europe's Pharma Game
May 16 REGN These 2 No-Brainer Growth Stocks Are Breaking New Ground
May 16 MYGN Insider Sale: President and CEO Paul Diaz Sells 227,844 Shares of Myriad Genetics Inc (MYGN)
May 16 MYGN Insider Sale: Director Lee Newcomer Sells 6,200 Shares of Myriad Genetics Inc (MYGN)
May 14 MOTS Motus GI GAAP EPS of -$0.88
May 14 MOTS Motus GI Reports First Quarter 2024 Financial Results and Provides Corporate Update
May 14 REGN Regeneron Pharmaceuticals Inc (REGN) RBC Capital Markets Global Healthcare Conference (Transcript)
May 14 REGN Evercore says biotech ‘winter is finally thawing’
May 14 IKNA Ikena Oncology reports Q1 GAAP EPS of -$0.33
May 14 BNR Burning Rock Announces ADS Ratio Change to Be Effective on May 15, 2024
May 13 IKNA Ikena Oncology Reports First Quarter 2024 Financial Results and Corporate Update
Colorectal Cancer

Colorectal cancer (CRC), also known as bowel cancer and colon cancer, is the development of cancer from the colon or rectum (parts of the large intestine). A cancer is the abnormal growth of cells that have the ability to invade or spread to other parts of the body. Signs and symptoms may include blood in the stool, a change in bowel movements, weight loss, and feeling tired all the time.Most colorectal cancers are due to old age and lifestyle factors, with only a small number of cases due to underlying genetic disorders. Some risk factors include diet, obesity, smoking, and lack of physical activity. Dietary factors that increase the risk include red meat, processed meat, and alcohol. Another risk factor is inflammatory bowel disease, which includes Crohn's disease and ulcerative colitis. Some of the inherited genetic disorders that can cause colorectal cancer include familial adenomatous polyposis and hereditary non-polyposis colon cancer; however, these represent less than 5% of cases. It typically starts as a benign tumor, often in the form of a polyp, which over time becomes cancerous.Bowel cancer may be diagnosed by obtaining a sample of the colon during a sigmoidoscopy or colonoscopy. This is then followed by medical imaging to determine if the disease has spread. Screening is effective for preventing and decreasing deaths from colorectal cancer. Screening, by one of a number of methods, is recommended starting from the age of 50 to 75. During colonoscopy, small polyps may be removed if found. If a large polyp or tumor is found, a biopsy may be performed to check if it is cancerous. Aspirin and other non-steroidal anti-inflammatory drugs decrease the risk. Their general use is not recommended for this purpose, however, due to side effects.Treatments used for colorectal cancer may include some combination of surgery, radiation therapy, chemotherapy and targeted therapy. Cancers that are confined within the wall of the colon may be curable with surgery, while cancer that has spread widely are usually not curable, with management being directed towards improving quality of life and symptoms. The five-year survival rate in the United States is around 65%. The individual likelihood of survival depends on how advanced the cancer is, whether or not all the cancer can be removed with surgery and the person's overall health. Globally, colorectal cancer is the third most common type of cancer, making up about 10% of all cases. In 2012, there were 1.4 million new cases and 694,000 deaths from the disease. It is more common in developed countries, where more than 65% of cases are found. It is less common in women than men.

Browse All Tags